Interestingly, between 35 and 40% of ME/CFS patients experience significant improvement in their health when treated with dichloroacetate, a well-known activator of PDH [74,75]. The gene discussed is PDP1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.